Type I IFNs, IFN-α and IFN-β, were well studied for the biological activities, and IFN-α but not IFN-β has been mainly tested for the anti-tumor actions in combination with anti-cancer agents in clinical settings. This evidence concerns the gene IFNA2 and cancer.